We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Despite Endo’s Efforts, Actavis’ Generic Opana ER Approved
Despite Endo’s Efforts, Actavis’ Generic Opana ER Approved
July 19, 2013
Actavis said July 12 the FDA has approved its ANDA for oxymorphone hydrochloride extended release tablets 5 mg, 10 mg, 20 mg, 30 mg and 40 mg — generic equivalents of five previously marketed formulations of Endo Health Solutions’ Opana ER.